The role of angiogenic growth factors in the immune microenvironment of glioma

Ge, Zhengmao; Zhang, Qi; Lin, Wei; Jiang, Xiaofan; Zhang, Yanyu

doi:10.3389/fonc.2023.1254694

Cited by 5 publications

(3 citation statements)

References 228 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These strategies mainly target the vascular endothelial growth factor (VEGF) signaling pathway (VEGF/VEGFR) ( 177 ), angiopoietin/Tie2 (Ang/Tie2) signaling pathway, and matrix metalloproteinases (MMPs) ( 178 , 179 ). It is well established that the platelet-derived growth factor/platelet-derived growth factor receptor (PDGF/PDGFR) axis also plays a key role in glioma angiogenesis ( 180 ). Han et al.…”

Section: Mscs-derived Exosomes (Mscs-exo) In Cancer Therapymentioning

confidence: 99%

Different origin-derived exosomes and their clinical advantages in cancer therapy

Jin,

Zhang,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Exosomes, as a class of small extracellular vesicles closely related to the biological behavior of various types of tumors, are currently attracting research attention in cancer diagnosis and treatment. Regarding cancer diagnosis, the stability of their membrane structure and their wide distribution in body fluids render exosomes promising biomarkers. It is expected that exosome-based liquid biopsy will become an important tool for tumor diagnosis in the future. For cancer treatment, exosomes, as the “golden communicators” between cells, can be designed to deliver different drugs, aiming to achieve low-toxicity and low-immunogenicity targeted delivery. Signaling pathways related to exosome contents can also be used for safer and more effective immunotherapy against tumors. Exosomes are derived from a wide range of sources, and exhibit different biological characteristics as well as clinical application advantages in different cancer therapies. In this review, we analyzed the main sources of exosomes that have great potential and broad prospects in cancer diagnosis and therapy. Moreover, we compared their therapeutic advantages, providing new ideas for the clinical application of exosomes.

show abstract

Section: Mscs-derived Exosomes (Mscs-exo) In Cancer Therapymentioning

confidence: 99%

Different origin-derived exosomes and their clinical advantages in cancer therapy

Jin,

Zhang,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…The platelet-derived growth factor (PDGF) family consists of four heparin-binding polypeptide growth factors (A, B, C, and D). It promotes vessel maturation, the recruitment of pericytes and VEGF upregulation [ 74 ]. The PDGF-B/PDGFRβ axis has been extensively explored [ 75 ].…”

Section: Introductionmentioning

confidence: 99%

Research progress of exosomes in the angiogenesis of digestive system tumour

Liu,

Wu,

Sang

et al. 2024

Discov Onc

View full text Add to dashboard Cite

Malignant tumours of the digestive system cover a wide range of diseases that affect the health of people to a large extent. Angiogenesis is indispensable in the development, and metastasis of tumours, mainly in two ways: occupation or formation. Vessels can provide nutrients, oxygen, and growth factors for tumours to encourage growth and metastasis, so cancer progression depends on simultaneous angiogenesis. Recently, exosomes have been proven to participate in the angiogenesis of tumours. They influence angiogenesis by binding to tyrosine kinase receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 with different affinities, regulating Yap-VEGF pathway, Akt pathway or other signaling pathway. Additionally, exosomes are potential therapeutic vectors that can deliver many types of cargoes to different cells. In this review, we summarize the roles of exosomes in the angiogenesis of digestive system tumours and highlight the clinical application prospects, directly used as targers or delivery vehicles, in antiangiogenic therapy.

show abstract

“…In particular, M2-like macrophages secrete pro-angiogenic factors, mainly VEGF, which promote the development of excessive and immature vessels [6,7]. Therefore, such a hostile microenvironment also limits CD8 + T and CD4 + Th1 cell infiltration [8][9][10] (Figure 1). Consequently, strategies to induce a TME permissive to immune cell infiltration are of major interest to improve the efficacy of immune therapy and reduce tumor growth.…”

Section: Introductionmentioning

confidence: 99%

Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy

Meo,

de Nigris

2024

Cancers

View full text Add to dashboard Cite

Abnormal vasculature in solid tumors causes poor blood perfusion, hypoxia, low pH, and immune evasion. It also shapes the tumor microenvironment and affects response to immunotherapy. The combination of antiangiogenic therapy and immunotherapy has emerged as a promising approach to normalize vasculature and unlock the full potential of immunotherapy. However, the unpredictable and redundant mechanisms of vascularization and immune suppression triggered by tumor-specific hypoxic microenvironments indicate that such combination therapies need to be further evaluated to improve patient outcomes. Here, we provide an overview of the interplay between tumor angiogenesis and immune modulation and review the function and mechanism of the YY1-HIF axis that regulates the vascular and immune tumor microenvironment. Furthermore, we discuss the potential of targeting YY1 and other strategies, such as nanocarrier delivery systems and engineered immune cells (CAR-T), to normalize tumor vascularization and re-establish an immune-permissive microenvironment to enhance the efficacy of cancer therapy.

show abstract

The role of angiogenic growth factors in the immune microenvironment of glioma

Cited by 5 publications

References 228 publications

Different origin-derived exosomes and their clinical advantages in cancer therapy

Different origin-derived exosomes and their clinical advantages in cancer therapy

Research progress of exosomes in the angiogenesis of digestive system tumour

Clinical Potential of YY1-Hypoxia Axis for Vascular Normalization and to Improve Immunotherapy

Contact Info

Product

Resources

About